Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 *ST新研(300159.SZ)公告称，公司因执行重整计划，将进行资本公积金转增股本，转增股份数量为 1,794,775,108股。公司股票将于12月23日停牌一个交易日，并于12月24日复牌。 ...

*ST新研12月22日公告，公司重整计划已于12月16日由乌鲁木齐中级法院裁定批准。根据重整计划，公 司因执行资本公积金转增股本共计转增17.95亿股股份，并拟定此次资本公积金转增股本的股权登记日 为12月23日。 为明确此次重整资本公积金转增股本的除权参考价格计算公式要素，经申请，于此次资本公积金转增股 本事项的股权登记日当天，公司股票停牌一个交易日，于12月24日复牌。 ...

格隆汇12月22日丨*ST新研(300159.SZ)公布，为明确本次重整资本公积金转增股本的除权参考价格计算 公式要素，经公司向深圳证券交易所申请，于本次资本公积金转增股本事项的股权登记日当天2025年12 月23日，公司股票停牌一个交易日。公司将向深圳证券交易所申请，于2025年12月24日复牌。 责任编辑：钟离 财经频道更多独家策划、专家专栏，免费查阅>> ...

为明确此次重整资本公积金转增股本的除权参考价格计算公式要素，经申请，于此次资本公积金转增股 本事项的股权登记日当天，公司股票停牌一个交易日，于12月24日复牌。 人民财讯12月22日电，*ST新研（300159）12月22日公告，公司重整计划已于12月16日由乌鲁木齐中级 法院裁定批准。根据重整计划，公司因执行资本公积金转增股本共计转增17.95亿股股份，并拟定此次 资本公积金转增股本的股权登记日为12月23日。 ...

*ST新研公告称，《新疆机械研究院股份有限公司重整计划》于2025年12月16日获乌鲁木齐中级人民法 院裁定批准。公司因执行资本公积金转增股本，将转增1,794,775,108股，股权登记日为2025年12月23 日。为明确除权参考价格计算公式要素，经申请，公司股票于12月23日停牌1个交易日，12月24日复 牌。 ...

*ST新研公告称，本次资本公积金转增股本以现有总股本14.96亿股为基数，按每10股转增12股实施，共 计转增17.95亿股，转增后总股本将增至32.90亿股。股权登记日为2025年12月23日，除权除息日和转增 股本上市日为12月24日。公司拟调整除权参考价格计算公式，若股权登记日收盘价高于转增股本平均价 2.45元/股，次日开盘参考价将调整。公司股票12月23日停牌1天，12月24日复牌。此外，公司提示股价 除权及破产、退市等风险。 ...

证券代码：300159 证券简称：*ST 新研 公告编号：2025-077 新疆机械研究院股份有限公司 关于公司股票停牌的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误 导性陈述或重大遗漏。 《新疆机械研究院股份有限公司重整计划》（以下简称"重整计划"）已于 2025 年 12 月 16 日由乌鲁木齐中级人民法院裁定批准。根据重整计划，公司因执行 资本公积金转增股本共计转增 1,794,775,108 股股份（最终转增股票准确数量以 中国证券登记结算有限责任公司深圳分公司实际登记确认的数量为准），并拟定 本次资本公积金转增股本的股权登记日为 2025 年 12 月 23 日。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所交易规则》 等有关规定，公司对本次重整计划实施资本公积金转增股本除权参考价格的计算 公式进行了调整，并由申万宏源证券承销保荐有限责任公司为公司调整资本公积 金转增股本除权参考价格的计算公式调整事项出具了专项意见，具体内容详见公 司于 2025 年 12 月 12 日披露的《关于重整计划资本公积金转增股本除权事项的 公告》（公告编号：2025-0 ...

证券代码：300159 证券简称：*ST 新研 公告编号：2025-076 新疆机械研究院股份有限公司 关于资本公积金转增股本实施后首个交易日开盘参考价调 整事项的第二次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假 记载、误导性陈述或重大遗漏。 特别提示： 由于本次资本公积金转增股本系重整程序中出资人权益调整的一部分，与一 般情形下的上市公司资本公积转增股本存在明显差异，公司根据《深圳证券交易 所交易规则》（2023 年修订）（以下简称《交易规则》）第 4.4.2 条的相关规定， 结合本次重整资本公积金转增股本的实际情况，调整除权参考价格计算公式。如 果股权登记日公司股票收盘价高于本次重整新研股份资本公积金转增股本的平 均价 2.45 元/股，公司股票按照前述拟调整后的除权（息）参考价于股权登记日 次一交易日调整开盘参考价，股权登记日次一交易日证券买卖，按上述开盘参考 价格作为计算涨跌幅度的基准；如果股权登记日公司股票收盘价低于或等于本次 重整新研股份资本公积金转增股本的平均价 2.45 元/股，公司股权登记日次一交 易日的股票开盘参考价无需调整。根据重整计划，结合公司初 ...

Group 1 - Sichuan Chengyu's wholly-owned subsidiary plans to acquire 85% equity of Hubei Jingyi Company for 2.409 billion yuan, enhancing the company's control over highway projects [1] - Huadian Technology signed contracts worth approximately 815 million yuan with Huadian Technology Group for a wind power hydrogen production project [2] - Dongfang Cable and its subsidiary won projects totaling approximately 3.125 billion yuan, accounting for 34.37% of the company's audited revenue for 2024 [3] Group 2 - Heng Rui Medicine received approval for clinical trials of SHR-2906 injection, a self-developed biopharmaceutical aimed at weight control and metabolic regulation [4] - Qingdao Port plans to invest approximately 15.7 billion yuan in two terminal projects [5] - Jingu Co. received a notification to supply low-carbon wheels for two export models to a major domestic car manufacturer, with production expected in 2026 [6] Group 3 - ST Xingguang won a procurement project worth approximately 22.955 million yuan, accounting for 11.96% of the company's revenue for 2024 [7] - Xinbo Co. plans to jointly invest in an alloy materials research institute with partners, focusing on high-performance materials for various industries [8] - Tianqi Lithium's third-phase lithium concentrate expansion project has been completed and is undergoing trial production, with a total capacity of 2.14 million tons per year [9] Group 4 - Changfei Fiber reported that new fiber optic products related to data centers represent a small proportion of total demand [10] - Dongfang Bio's subsidiaries obtained multiple medical device registration certificates, including various testing kits [11] - Xiugang Co. plans to use up to 500 million yuan of idle fundraising for cash management in safe, liquid investment products [12] Group 5 - Jifeng Co. received a project designation for passenger car seat assemblies from a European luxury brand, with a total lifecycle value of approximately 9.8 billion yuan [13] - CanSino initiated Phase I clinical trials for a combined vaccine, completing the first subject enrollment [14] - Dayu Water-saving's subsidiary pre-won a drainage project worth 140 million yuan and another project worth 1 billion yuan [15] Group 6 - Yutong Pharmaceutical's subsidiary received clinical trial approval for YKYY032 injection for treating hyperlipoproteinemia [17] - Diweier announced the departure of a core technical personnel, impacting its technical leadership [18] - Weilang Co.'s controlling shareholder received regulatory measures from the Shandong Securities Regulatory Bureau for failing to fulfill a commitment [19] Group 7 - Xiehe Electronics invested 5 million yuan in a private equity fund focusing on hard technology sectors [20] - Phoenix Optical received a government subsidy of 4.7053 million yuan, representing 35% of its projected net profit for 2024 [21] - China State Construction reported a 0.9% year-on-year increase in new contracts signed in the first 11 months of 2025, totaling 4.0408 trillion yuan [22] Group 8 - Nanguang Energy's pumped storage power station units 1 and 2 have entered trial operation, with units 3 and 4 expected to follow by year-end [23] - Jindalai plans to invest 280 million yuan to acquire a 34% stake in Yunnan Jici Medical Technology [24] - Geer Software terminated its planned acquisition of a majority stake in Weipin Zhiyuan due to failure to reach agreement on key terms [25] Group 9 - Ningbo Fubang completed the absorption merger of its wholly-owned subsidiary, inheriting all assets and liabilities [26] - Zhongyuan Neipei signed a strategic cooperation framework agreement with Ningbo Puzhi Company for humanoid robot-related business [28] - Gongyuan Co. announced a business integration and relocation of its production lines in the East China region [29] Group 10 - Chlor-alkali Chemical's subsidiary plans to invest 2.975 billion yuan in a comprehensive utilization project for waste salt [30] - Kain Technology announced the departure of a core technical personnel, impacting its research capabilities [31] - ST Renfu received approval for clinical trials of a new drug for idiopathic pulmonary fibrosis [32] Group 11 - Sanbo Brain Science's established brain science fund has completed registration with the Asset Management Association of China [33] - Tongyou Technology plans to apply for a 70 million yuan credit line from Beijing Bank, using its property as collateral [34] - Bai Ao Intelligent signed a significant equipment sales contract worth approximately 27.5021 million yuan [35] Group 12 - ST Xinyan received all restructuring investment funds totaling 2.239 billion yuan, entering the execution phase of its restructuring plan [36] - Dalu Real Estate's subsidiary decided to terminate a planned acquisition of a 60% stake in Beijing Chengzhu Real Estate [38] - Huiyu Pharmaceutical's products received marketing approval in Italy and Norway [39]